2137 — Brii Biosciences Share Price
0.000.00%
Last trade - 00:00- HK$1.44bn
- -HK$1.06bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.51 | ||
| Price to Tang. Book | 0.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.4% | ||
| Return on Equity | -17.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 51.63 | 0.62 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Brii Biosciences Ltd is a biotechnology company principally focused on developing therapies for infectious diseases and central nervous system diseases. The Company's HBV portfolio products include the proprietary therapeutic vaccine BRII-179, the siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). The Company owns a broad pipeline of multiple innovative drug candidates that focus on infectious diseases and central nervous system diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The Company mainly conducts its businesses in China market.
Directors
- Zhi Hong CHM (58)
- Yongqing Luo PRE (51)
- Ankang Li CFO (43)
- Lisa Beck SVP (59)
- Jean-luc Girardet SVP (54)
- Lianhong Xu SVP (55)
- Qing Zhu SVP (53)
- Li Yan OTH (53)
- Wing Tsz Ho SEC
- Axel Bouchon NED (48)
- Robert Nelsen NED (58)
- Gregg Alton NID (55)
- Martin Murphy NID (78)
- Hui Tang NID (61)
- Yiu Wa Tsui NID (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 8th, 2017
- Public Since
- July 13th, 2021
- No. of Employees
- 95
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 719,177,610
- Address
- 3rd Floor, Building 7, BEIJING, 100192
- Web
- https://www.briibio.com/
- Phone
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 2137
Brii Biosciences Ltd Annual Shareholders Meeting
Half Year 2025 Brii Biosciences Ltd Earnings Release
Similar to 2137
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Brii Biosciences share price?
As of Today at 19:41 UTC, shares in Brii Biosciences are trading at HK$2.00. This share price information is delayed by 15 minutes.
How has the Brii Biosciences share price performed this year?
Shares in Brii Biosciences last closed at HK$2.00 and the price had moved by +83.49% over the past 365 days. In terms of relative price strength the Brii Biosciences share price has outperformed the FTSE Developed Asia Pacific Index by +85.58% over the past year.
What are the analyst and broker recommendations for Brii Biosciences?
The overall consensus recommendation for Brii Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Brii Biosciences dividend yield?
Brii Biosciences does not currently pay a dividend.
Does Brii Biosciences pay a dividend?
Brii Biosciences does not currently pay a dividend.
When does Brii Biosciences next pay dividends?
Brii Biosciences does not currently pay a dividend.
How do I buy Brii Biosciences shares?
To buy shares in Brii Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Brii Biosciences?
As of the previous close price of HK$2.00, shares in Brii Biosciences had a market capitalisation of HK$1.44bn.
Where are Brii Biosciences shares listed?
Here are the trading details for Brii Biosciences:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2137
What kind of share is Brii Biosciences?
Based on an overall assessment of its quality, value and momentum Brii Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Brii Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Brii Biosciences is HK$1.00. That is 50.01% below the last closing price of HK$2.00.
Analysts covering Brii Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.45 for the next financial year.
Find out moreWhat is the trend in the Brii Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Brii Biosciences. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +103.77%.
As of the last closing price of HK$2.00, shares in Brii Biosciences were trading +56.07% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Brii Biosciences PE Ratio?
The Brii Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Brii Biosciences?
Brii Biosciences' management team is headed by:
- Zhi Hong - CHM
- Yongqing Luo - PRE
- Ankang Li - CFO
- Lisa Beck - SVP
- Jean-luc Girardet - SVP
- Lianhong Xu - SVP
- Qing Zhu - SVP
- Li Yan - OTH
- Wing Tsz Ho - SEC
- Axel Bouchon - NED
- Robert Nelsen - NED
- Gregg Alton - NID
- Martin Murphy - NID
- Hui Tang - NID
- Yiu Wa Tsui - NID